William Dai is the Founding Managing Partner of ShangBay Capital, a leading early stage Medtech-focused VC based in Palo Alto, California. Since the founding of ShangBay Capital in 2015, William has led ShangBay to become a very successful VC with 60 portfolio companies to date and multiple successful exits. William currently serves on the board of directors for several companies, including SetPoint Medical, Aqua Medical, Emboline, Meditrina, Corinth Medtech, FemDx, Apostle, Yorlabs, Laplace Interventional, Luminopia, Early Bird Medical and previously served on the board of directors for NeuroVasc (acq in 2019) and Arrinex (acq by Stryker in 2019).

 

William’s prior work experiences spanned more than 20 years in corporate finance, mergers and acquisitions, and capital markets in both Asia and the U.S. Prior to founding ShangBay Capital, he was the CFO of ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK:00853), and Boston Scientific China. In these roles, William was responsible for the overall execution of business transactions to drive business success. He began his career at the Ford Motor Company in Michigan as a Finance Manager of the Treasury department.

 

He is well-respected among financial and investment circles and is a recognized leader in the industry. In addition, due to his hands-on experience leading multiple large international medical device companies, he has a very in-depth knowledge of the medical device industry and its market dynamics.

 

William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan State University.